hypertensive patients with chronic kidney disease
Conditions
Interventions
cilnidipine(initial dose is 10mg/day, 5-20mg/day)
azelnidipine(initial dose is 8mg/day, 4-16mg/day)
Sponsors
Department of Cardiology and Nephrology, Mie University, Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hypertension patients with chronic kidney disease (CKD) *Chronic kidney disease is defined as either kidney damage or GFR<60ml/min/1.73m^2 for 3months. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies. Patients who administer angiotensin receptor blocker(ARB) and amlodipine as calcium blocker.
Exclusion criteria
Exclusion criteria: 1) Contraindication to calcium chanel blockers. 2) Patients who has already administered calcium channel blocker except for amlodipine. 3) Any serious comobidity(brain disease, heart disease, renal disease, hepatic disease) 4) The patients with pregnant or possibly pregnant 5) Sereous hypertension patients 6) Investigator judged as inappropriate for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary albumin-creatinie ratio(mg/g*Cr) after 12 and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical blood pressure and heart rate Mean home blood pressure Estimated glomerular filtration rate Plasma Renin Activity, Plasma Aldosterone Concentration Antihypertensive effect Safety parameters will be analized after 12 and 24 weeks | — |
Countries
Japan
Contacts
Public ContactMasaya Taniguchi
Mie University, Graduate School of Medicine Department of Cardiology and Nephrology
Outcome results
None listed